Genmab A/S (FRA:GE91)
Germany · Delayed Price · Currency is EUR | Market Cap | 15.67B +27.6% |
| Revenue (ttm) | 3.38B +20.7% |
| Net Income | 712.05M -27.7% |
| EPS | 11.37 -25.8% |
| Shares Out | n/a |
| PE Ratio | 22.01 |
| Forward PE | 21.24 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 25.00 |
| Previous Close | 25.20 |
| Day's Range | 25.00 - 25.00 |
| 52-Week Range | 18.20 - 29.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Genmab
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell n... [Read more]
Financial Performance
In 2025, Genmab's revenue was $3.72 billion, an increase of 19.19% compared to the previous year's $3.12 billion. Earnings were $963.00 million, a decrease of -15.00%.
Financial numbers in USD Financial StatementsNews
AbbVie (ABBV) and Genmab's Epcoritamab Fails Key Trial Endpoint
AbbVie (ABBV) and Genmab's Epcoritamab Fails Key Trial Endpoint
Genmab & AbbVie's Epcoritamab Fails To Meet Primary Goal In Phase 3 EPCORE DLBCL-1 Trial
(RTTNews) - Genmab A/S (GMAB) and AbbVie Inc. (ABBV) on Thursday announced that the Phase 3 EPCORE DLBCL-1 trial evaluating Epcoritamab in adults with relapsed or refractory (R/R) diffuse large B-cell...
Genmab, AbbVie provide clarification on Phase 3 EPCORE(R) DLBCL-1 trial
Genmab A/S (GMAB) and AbbVie (ABBV) provided clarification on the primary endpoints from the Phase 3 EPCORE(R) DLBCL-1 study evaluating monotherapy epcoritamab (DuoBody(R)-CD3xCD20), a T-cell engaging...
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
COPENHAGEN, Denmark & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today provided clarification on the primary endpoints from the Phase 3 EPCORE® DLBCL-1 stu...
Genmab upgraded to Buy from Hold at TD Cowen
TD Cowen analyst Yaron Werber upgraded Genmab (GMAB) to Buy from Hold with a price target of $43, up from $32. The firm is confident that Epkinly, rinatabart sesutecan and…
Genmab Reports Q2 Worldwide Net Trade Sales Of DARZALEX
NEW BRUNSWICK (dpa-AFX) - Genmab A/S (GMAB) announced that worldwide net trade sales of DARZALEX, including sales of the subcutaneous product, as reported by J&J were $4.207 billion in the second ...
Genmab reports Q2 net sales of Darzalex $4.207B
Genmab (GMAB) announced that worldwide net trade sales of DARZALEX, or daratumumab, including sales of the subcutaneous, or SC, product, daratumumab and hyaluronidase-fihj, sold under the tradename DA...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026
Company Announcement Net sales of DARZALEX ® in the second quarter of 2026 totaled USD 4,207 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen ...
Genmab Announces Net Sales of DARZALEX (daratumumab) for Second Quarter of 2026
Company Announcement Net sales of DARZALEX in the second quarter of 2026 totaled USD 4,207 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Bi...
Genmab Wins EU Nod For TEPKINLY Combo In Follicular Lymphoma
(RTTNews) - Genmab A/S (GMAB) announced that the European Commission has approved TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patie...
Genmab says EC grants marketing authorization for Tepkinly combo
Genmab (GMAB) announced that the European Commission granted marketing authorization for TEPKINLY in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or re...
Genmab A/S: Genmab Announces TEPKINLY (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
TEPKINLY (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Europe for the treatment of follicular lymphoma in the second-line setting, o...
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenali...
Genmab Announces TEPKINLY (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) granted marketing authorization for TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) fo...
Genmab price target raised to $40 from $38 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Genmab (GMAB) to $40 from $38 and keeps a Buy rating on the shares after the company announced that…
Genmab Shares Climb After Lymphoma Therapy Hits Goal in Trial
The Danish biotechnology company and partner AbbVie said a drug combination to treat lymphoma met the primary goal in a late-stage clinical trial.
Genmab (GMAB) Reports Positive Phase 3 Trial Results for Epcoritamab
Genmab (GMAB) Reports Positive Phase 3 Trial Results for Epcoritamab
Genmab announces topline results from EPCORE DLBCL-4 trial
Genmab (GMAB) announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of fixed duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneousl...
Genmab reports ‘positive’ Phase 3 results from EPCORE DLBCL-4 trial
Genmab (GMAB) announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of fixed duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneousl...
Genmab A/S: Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
Company Announcement Topline results from Phase 3 EPCORE DLBCL-4 evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvemen...
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
Company Announcement Topline results from Phase 3 EPCORE ® DLBCL-4 evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; June 16, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 185 shares as a consequence of the exercise of employee warrants. The increase is...
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; June 15, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets ...
Genmab (GMAB) Reports Promising Results for Epcoritamab in DLBCL Studies
Genmab (GMAB) Reports Promising Results for Epcoritamab in DLBCL Studies
Genmab announces new data from studies evaluating epcoritamab
Genmab (GMAB) announced new data from two studies evaluating epcoritamab. Results from the Phase 2 EPCORE DLBCL-3 study showed an overall response rate, ORR, of 67% and a complete response…